Remitly Global Inc vs Viatris Inc — how do they compare? Remitly Global Inc trades at $23.37 (market cap $5.02B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 4.1× Remitly Global Inc's market cap, and Viatris Inc pays a 2.73% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| RELY | VTRS | |
|---|---|---|
Market Cap | $5.02B | $20.50B |
Sector | Technology | Health |
52-Week High | $25.23 | $17.59 |
52-Week Low | $12.20 | $8.74 |
Enterprise Value | $4.41B | $32.71B |
Dividend Yield | — | 2.73% |
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.83, down 1.24% on the day, with a bullish technical signal from moving averages. The company has demonstrated a strong turnaround, achieving profitability in 2025 with net income of $67.93 million after years of losses. Revenue growth is robust, reaching $1.64 billion in 2025, with positive cash flow from operations of $325.08 million. Recent news highlights expansion, including a new license in the UAE and raised full-year guidance for 2026.
The outlook is positive, driven by accelerating revenue growth, market share gains in the remittance sector, and a clear path to sustained profitability. Key risks include intense competition from established payment giants and execution challenges in international expansion. With a consensus analyst price target of $28.50 implying significant upside, the stock presents a growth opportunity, though investors should be mindful of its premium valuation multiples.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →